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2ABSTRACT
The microtubule-associated STOP (Stable Tubule Only Polypeptide) protein
plays a key-role in neuron architecture and synaptic plasticity. Recent studies
suggest that schizophrenia is associated with alterations in the synaptic
connectivity. Mice invalidated for the STOP gene display phenotype reminiscent
of some schizophrenic-like symptoms, such as behavioral disturbances, dopamine
hyper-reactivity and possible hypoglutamatergia, partly improved by
antipsychotic treatment. In the present work, we examined potential alterations
in some dopaminergic key proteins and behaviors in STOP knock-out mice.
Whereas the densities of the dopamine transporter, the vesicular
monoamine transporter and the D1 receptor were not modified, the densities of
the D2 and D3 receptors were decreased in some dopaminergic regions in mutant
versus wild-type mice. Endogenous dopamine levels were selectively decreased in
dopaminergic terminals areas, although the in vivo dopamine synthesis was
diminished both in cell bodies and terminal areas. The dopamine uptake was
decreased in accumbic synaptosomes, but not significantly altered in striatal
synaptosomes. Finally, STOP knock-out mice were hypersensitive to acute and
sub-chronic locomotor effects of cocaine, although the drug equally inhibited
DA uptake in mutant and wild-type mice.
Altogether, these data showed that deletion of the ubiquitous STOP
protein elicited restricted alterations in dopaminergic neurotransmission,





















Microtubules are key cytoskeletal components in neurons, where they play a role
in morphogenesis and protein transport in dendrites and axons. Previous work
has indicated a central role for one of the microtubule-associated proteins,
called STOP (Stable Tubule Only Polypeptide or MAP1B) in neuron stabilization
and synaptic plasticity (Bosc et al. 1996; Guillaud et al. 1998; van Rossum and
Hanisch 1999).
The recently engineered mouse line deficient in the STOP protein
(Andrieux et al. 2002) exhibits synaptic defects in the hippocampus. They
include depleted glutamatergic vesicle pool and marked decrease in long-term
potentiation and depression in the CA1 field (Andrieux et al. 2002; Zervas et al.
2005). Moreover, levels of mRNAs encoding synaptic proteins, such as
synaptophysin, growth associated protein-43 and spinophilin, are decreased in
some hippocampic sub-regions (Eastwood et al. 2006). Moreover, a recent report
shows indirect evidence for decreased glutamate release in the CNS of mutant
mice (Brenner et al. 2007). STOP knock-out (KO) mice show severe behavioral
disturbances, namely purposeless and disorganized locomotor activity, impaired
social interactions and maternal behavior, deficits in the prepulse inhibition
(PPI) of the startle reflex, hypersensitivity to mild stress and to the stimulant
locomotor effect of amphetamine (Andrieux et al. 2002; Brun et al. 2005;
Fradley et al. 2005). STOP KO mice also display dopamine (DA) hyper-reactivity,
preferentially in the limbic dopaminergic system (Brun et al. 2005). Whereas
basal extracellular DA levels are not modified in the striatum and the nucleus
accumbens, electrically evoked DA release is selectively increased in the nucleus
accumbens of STOP KO mice. Some of the behavioral and synaptic deficits in
STOP KO mice can partly be restored by chronic antipsychotic drug treatment
(Andrieux et al. 2002; Brun et al. 2005). Altogether, the behavioral
disturbances, the DA hyper-reactivity in limbic system and the indirect evidence
of a decreased glutamatergic neurotransmission suggest that STOP KO mice
may represent a pertinent experimental model for some schizophrenic
symptoms. Interestingly, we recently report that nicotinic neurotransmission can
be deficient in STOP KO mice, despite of increased nicotinic α7 receptor
density in some brain areas, and that mutant mice display cognitive deficits
improved by the rather selective α7 receptor agonist choline (Bouvrais-Veret et
al. 2007).
Several lines of evidence suggest that schizophrenia is associated with
alterations of neuronal architecture, particularly in the synaptic connectivity
(Mirnics et al. 2001; Frankle et al. 2003; Benitez-King et al. 2004; Owen et al.




















4demonstrated to bind to microtubules and its truncation in schizophrenic
patients contributes to impair intraneuronal transport, neurite cytoarchitecture
and/or neuronal migration (Morris et al. 2003; Owen et al. 2005a; Ishizuka et al.
2006). Furthermore, the MAP6 gene, the human homologous of STOP gene, is
localized on chromosome 11q14, a region highly associated with schizotypal
personality disorders (Lewis et al. 2003). Interestingly, an association between
single nucleotide polymorphism markers of the MAP6 gene and schizophrenia has
been recently published, together with an up-regulation of the isoform 2 of
MAP6 transcripts in the frontal cortex of schizophrenic patients (Shimizu et al.
2006).
Thus, the STOP KO mice, which represent a pertinent experimental model
for some schizophrenic related symptoms, are likely to be informative to
understand how possible structural-related changes may translate into
dysfunctions of neutransmitter systems, especially DAergic neurotransmission.
So, we investigated various DA neuron-related markers: the densities of the DA
transporter (DAT), the vesicular monoamine transporter 2 (VMAT2) and the D1,
D2 and D3 DAergic receptors in various brain areas in STOP KO compared to
wild-type (WT) mice. We also measured the endogenous DA and metabolite
levels and the in vivo DA synthesis rate in various brain areas containing DAergic
cell bodies and terminals. DA uptake and its inhibition by cocaine were measured
using striatal and accumbic synaptosomes. Finally, we assessed the effects of























Homozygous STOP KO mice and their WT littermates were obtained by crossing
(F2) heterozygous 50:50 BALBc/129 SvPas-F1. The genotype of mice was
determined from tail biopsies as previously described (Andrieux et al. 2002).
Animals were housed 4-6 per cage by litter, gender and genotype. They were
kept under standard conditions, with food and water available ad libitum,
temperature at 23±2°C, humidity at 55±10% and a 12 h light:12 h dark cycle,
with lights on at 07:30 a.m.. Experiments were carried out in accordance with
the European Communities Council directive (86/809/EEC) and approved by the
local ethical committee. Mice were allowed to habituate to the animal holding
room for at least one week prior to use. All experiments were conducted with 99
WT and 99 KO mice (about 60%/40% females/males), of the same litters and at
3-4 months of age.
Drugs
(±)-Butaclamol hydrochloride, 1,3-di-o-tolylguanidine, dopamine hydrochloride,
NSD 1015 (3-hydroxybenzyl-hydrazine) were purchased from Sigma-Aldrich
(Saint Quentin-Fallavier, France). Apomorphine hydrochloride was purchased
from Tocris (Bristol, UK). Ascorbate oxidase and nomifensine maleate were
purchased from RBI (Natik, USA) and cocaine hydrochloride from Cooper
(Melun, France). Cocaine and NSD 1015 were dissolved in 0.9% NaCl as free base
and were administered intraperitoneally (i.p.) under a volume of 100 µl per 20 g
body weight. Polyclonal antibody against VMAT2 was from Phoenix Europe GMBH
(Karlsruhe, Germany). [7,8-3H]-Dopamine (1.5-2.2 Tbq/mmol),  rabbit [125I]-Ig F
(ab’)2 fragment antibodies (28-111 TBq/mmol), [125I]-iodosulpride (74 TBq/mmol)
and [N-methyl-3H]-SCH 23390 (2.2-3.3 TBq/mmol) were from GE Healthcare
(Orsay, France). [125I]-R(±)trans-7-hydroxy-2-[N-(3’-iodo-2’-propenyl)amino]
tetralin ([125I]-7-OH-PIPAT, 81.4 TBq/mmol) was from Perkin Elmer-NEN
(Orsay, France).
Before use, [125I]-IgG antibodies were purified by gel filtration onto a
PD10 column (Sephadex G25 M, Pharmacia) in PBS (50 mM NaH2PO4/Na2HPO4,
154 mM NaCl) containing 0.1% gelatin. The first 0.25 ml eluate was discarded
and the following 3.5 ml eluate was mixed with 400 ml PBS supplemented with
3% bovine serum albumin (BSA), 1% goat serum, 1 mM NaI and 0.02% sodium





















Mice were killed by cervical dislocation between 10:00 a.m. and 4:00 p.m. and
their brains rapidly removed and frozen in isopentane at –30°C. Serial 10 µm
coronal sections were cut at –20°C, thaw-mounted on Superfrost Plus® slides
and stored at –80°C until use.
Immunoautoradiography of dopamine transporter (DAT) and vesicular monoamine
transporter (VMAT2)
Brain sections were fixed with 4% paraformaldehyde for 15 min at room
temperature, washed with PBS and then incubated for 1 h at room temperature
in PBS containing 3% BSA, 1% goat serum and 1 mM NaI. Sections were
subsequently incubated for 2 h at room temperature (or overnight at 4°C) in the
presence of polyclonal DAT antiserum (1:20,000 dilution, Martres et al. 1998) or
polyclonal VMAT2 antiserum (1:8,000 dilution). After extensive washes, slides
were incubated for 2 h at room temperature with purified anti-rabbit [125I]-IgG
(370-740 MBq/100 ml). Sections were extensively washed with PBS, dried and
exposed to Biomax MR film for 1-4 days.
Autoradiographic determination of D1, D2 and D3 DAergic receptor densities
To rule out possible binding of endogenous DA to its receptors, sections were
pre-incubated in buffer before addition of radioactive ligands.
Labelling of D1 receptors was performed according to Fernagut et al.
(2003). Slides were pre-incubated for 20 min at room temperature in 50 mM
Tris-HCl buffer, pH 7.4, containing 120 mM NaCl, 5 mM KCl, 2 mM CaCl2 and 1
mM MgCl2 (Tris-ions buffer). They were then incubated for 90 min at room
temperature in a fresh Tris-ions buffer containing 3 nM [3H]-SCH 23390, with
or without 10 µM butaclamol to determine non-specific binding. After four
washes for 5 min with ice-cold Tris-ions buffer, sections were dipped in ice-cold
water, dried and exposed to BAS-TR Fuji Imaging screen for 3 days. The
screens were scanned with a Fuji Bioimaging Analyzer BAS-5000.
Labelling of D2 receptors was done according to Martres et al. (1985).
Slides were pre-incubated three times for 5 min at room temperature in Tris-
ions buffer supplemented with 0.1% BSA and 0.57 mM ascorbic acid. They were
then incubated for 60 min at room temperature in Tris-ions buffer in the
presence of 0.2 nM [125I]-iodosulpride, with or without 10 µM apomorphine to
determine non-specific binding. Sections were washed as described for D1
receptor labelling and exposed to Biomax MR film (GE Healthcare) for 12-36 h.
Labelling of D3 receptors was performed according to Stanwood et al.
(2000), with some modifications: slides were pre-incubated three times for 5




















7mM EDTA, 2.8 mM ascorbic acid, 0.1% BSA, 100 µM GTP (to dissociate D2
receptors from G proteins) and 25 µM 1,3-di-o-tolylguanidine (to prevent the
labelling of σ  receptors). Then, sections were incubated for 60 min at room
temperature in the same buffer in the presence of 0.25 nM [125I]-7-OH-PIPAT,
with or without 10 µM dopamine to determine non-specific binding. Sections
were washed four times for 15 min each in ice-cold HEPES buffer, dipped in ice-
cold water, dried and exposed to Biomax MR film for 1-3 days.
Quantification
Standard radioactive microscales (GE Healthcare) were exposed onto each
Imaging screen or autoradiographic film to ensure that labelling densities were
in the linear range. The autoradiograms were scanned and densitometry was
performed with Multi Gauge software or MCIDTM analysis software for [3H]- or
[125I]-radioligand, respectively. Specific labelling densities (mean grey values in
arbitrary units) of four sections per area were averaged for each mouse.
Determination of tissue levels of DA and its metabolites and of in vivo
tyrosine hydroxylase activity
The levels of endogenous DA, its precursor L-DOPA and its metabolites DOPAC
and HVA were determined as follows: dissected brain areas were homogenized in
5-10 vol (v/w) of ice-cold 0.1 M HClO4 containing 0.05% EDTA and 0.05%
Na2S2O5. Homogenates were centrifuged at 22,500 g for 20 min at 4 °C. After
neutralization with 2 M KH2PO4/K2HPO4, pH 7.4, containing 0.01 mg/ml
ascorbate oxidase, supernatants were further centrifuged at 30,000 g for 10
min. Aliquots (10 µl) of clear supernatants were injected into a HPLC column
(Ultrasphere IP, Beckman, Gagny, France; 25x4.6 cm, C18 reversed-phase,
particle size 5 µm) protected with a Brownlee precolumn (3 cm, 5 µm). The
mobile phase for the elution (flow rate:  1 ml/min) consisted of 70 mM KH2PO4,
2.1 mM triethylamine, 0.1 mM EDTA, 1.25 mM octane sulphonate and 16%
methanol, adjusted to pH 3.02 with solid citric acid. The electrochemical
detection system (ESA 5011, Bedford, USA) comprises an analytical cell with
dual coulometric monitoring electrodes (+50 mV and +350 mV). The generated
signal was integrated by a computing integrator (Millenium32-Waters, Saint
Quentin Fallavier, France). Quantitative determinations were made using
appropriate standards.
For the in vivo measurement of tyrosine hydroxylase activity, animals
were intraperitoneally injected with 100 mg/kg NSD 1015, to block aromatic L-
amino acid decarboxylase, 30 min before sacrifice. Accumulated L-DOPA levels





















8Synaptosomal uptake of [3H]-DA
Pooled striata or nuclei accumbens from 2 mice were homogenized in 15-20
volumes (v/w) of ice-cold 0.32 M sucrose with a glass-Teflon potter (Braun
Biotech International; Sartorius, Palaiseau, France). Homogenates were diluted
to 40 volumes (v/w) with 0.32 M sucrose, centrifuged at 1,000 g for 10 min at 4
°C and the resulting supernatants were centrifuged again at 30,000 g for 10 min.
The pellets were gently homogenized in 50 volumes of 0.32 M sucrose and 25 µl
aliquots were incubated in a final volume of 500 µl of buffer containing 4 mM
Tris-HCl, 6.25 mM HEPES, 120 mM NaCl, 5 mM KCl, 1.2 mM CaCl2, 1.2 MgSO4,
5.6 mM D-glucose and 0.5 mM ascorbic acid, pH 7.4. For saturation experiments,
synaptosomes were incubated in the presence of 20 nM [3H]-dopamine plus 0.01-
1.0 µM unlabelled DA. For cocaine inhibition experiments, synaptosomes were
incubated in the presence of 10 nM [3H]-dopamine with or without 0.03-3.0 µM
cocaine. In all cases, non-specific uptake was determined in the presence of 30
µM nomifensine. After 7 min at 37 °C, samples were diluted with 3 ml of ice-cold
buffer and rapidly filtered through Whatman GF/B glass fibers presoaked with
0.05% polyethylenimine. After three washes with 3 ml of ice-cold buffer, filters
were dried and the entrapped radioactivity counted by liquid scintillation
spectrometry. Proteins were quantified according to Lowry et al. (1951) with
BSA as standard.
Locomotor activity 
In both experiments, mice were tested for their locomotor activity between
9:00 and 12:00 a.m..
Acute effect of cocaine
The horizontal locomotion activity was assessed in transparent activity cages
(20 x 15 x 25 cm), with automatic monitoring of photocell beam breaks, located
at 1.5 cm above the floor (Imetronic, Bordeaux, France). Mice were allowed to
habituate to actimeter cages 20 min before i.p. administration of saline or 5-40
mg/kg cocaine. Their locomotor activity was further recorded for 50 min.
Behavioral sensitization to cocaine
Mice were allowed to habituate to actimeter cages during 20 min before
administration of the drug. Animals of both genotypes received saline or cocaine
(10 mg/kg i.p.) for 5 consecutive days (initiation phase) and their locomotor
activity was recorded for 60 min after each administration. Twenty days after
the last saline or cocaine administration (day 25), all pre-treated mice received




















9received cocaine (10 mg/kg i.p.) and their locomotion was further recorded for
60 min.
Statistical analyses
For autoradiographic quantifications, determinations of endogenous DA and
metabolite levels and tyrosine hydroxylase activity, data were subjected to
factorial one-, two- or three-way analysis of variance (ANOVA), with genotype,
sex and area as between-group factors. Significant main effects were further
analyzed by post hoc comparisons of means using Fisher’s test.
The kinetic parameters of uptake experiments with synaptosomes, i.e. Km,
Vmax and IC50, were calculated by non-linear regression using GraphPad Prism
2.01 software (San Diego, USA). Inhibition constants (Ki) were calculated from
IC50 values using the following equation: Ki=IC50/(1+L/Km), where L represents
the concentration of [3H]-DA and Km the affinity constant of DA. The means ±
SEM were then compared using Student's t test.
Behavioral data were subjected to factorial two-, three- or four-way
ANOVA, with genotype, sex and treatment as between-group factors and time
as within-group factor. Significant main effects were further analyzed by post























No statistically significant differences were noted between males and females
of each genotype in all experimental conditions (not shown). Accordingly, data
for males and females in the studies reported therein were pooled.
DA transporters and receptors in various brain areas of STOP KO versus
WT mice
The densities of the DA transporter (DAT), the vesicular monoamine
transporter 2 (VMAT2) and the D1, D2 and D3 DAergic receptors were
determined in various brain areas of WT and STOP KO mice (Fig. 1 and Tables 1,
2). Analyses of the densities of DAT, VMAT2 and D1 receptors in the various
areas studied showed no significant effect of genotype.
Analysis of the density of D2 receptors showed a significant effect of
genotype and area (genotype: F(1,49)=16.31, p<0.001; area: F(5,49)=76.9, p<0.001).
The density of D2 receptors was decreased by 23% in the striatum (p=0.027), by
28% in the nucleus accumbens (p=0.015), by 28% in the core (p=0.014) and by
27% in the shell (p=0.018). No differences in D2 receptor density were noted in
the pars compacta of the substantia nigra and in the ventral tegmental area
between the two mouse strains (Table 2).
Analysis of the density of D3 receptors showed a significant effect of
genotype and area (genotype: F(1,75)=29.73, p<0.001; area: F(7,75)=177.5, p<0.001;
genotype x area: F(7,75)=3.43, p=0.003). The density of D3 receptors was
significantly decreased by 24% in the median pars compacta of the substantia
nigra (p=0.017), 37% in the ventral tegmental area (p=0.006), 18% in the nucleus
accumbens (p=0.050), by 24% in the core (p=0.011) and 21% in the shell
(p=0.027), while its density was not modified in the other DAergic areas
examined. The amplitude of the changes in the D3 receptor density was
significantly larger in the ventral tegmental area (p=0.019) and the nucleus
accumbens (p=0.007) than in the substantia nigra and the striatum, respectively.
Tissue levels of DA and its metabolites DOPAC and HVA
The levels of endogenous DA and its metabolites DOPAC and HVA in some
DAergic areas were compared between STOP KO and WT mice (Table 3).
Analyses of the data showed a significant effect of genotype and area on DA
levels (genotype: F(1,34)=25.49, p<0.001; area: F(3,34)=170.6, p<0.001; genotype x
area: F(3,34)=8.87, p<0.001), DOPAC levels (genotype: F(1,37)=19.38, p<0.001; area:
F(3,37)=61.44, p<0.001; genotype x area: F(3,37)=3.99, p=0.015) and HVA levels






















No significant differences in DA levels were found between mice of the
two genotypes in the substantia nigra plus the ventral tegmental area and in the
frontal cortex. In contrast, DA levels were significantly lower in the striatum (-
29%, p<0.001) and in the nucleus accumbens (-63%, p<0.001). The levels of
DOPAC were not significantly modified in the substantia nigra plus the ventral
tegmental area and the frontal cortex, but they were decreased by 23% in the
striatum (p=0.011) and by 53% in the nucleus accumbens (p<0.001). The level of
HVA was not modified in the substantia nigra plus the ventral tegmental area
and the frontal cortex, but it was decreased by 24% in the striatum (p=0.002)
and by 50% in the nucleus accumbens (p<0.001). In the latter two areas, the
DOPAC and HVA levels were decreased to the same extent as DA levels in STOP
KO mice, so that the ratio of metabolites over DA was not modified as compared
to that in WT mice (see Fig. 2).
Interestingly, the amplitudes of the STOP KO-associated decreases were
significantly two-fold higher in the nucleus accumbens than in the striatum for
DA (p=0.050), DOPAC (p=0.025) and HVA levels (p=0.010).
In vivo tyrosine hydroxylase activity in various brain areas
The in vivo activity of tyrosine hydroxylase (TH) was determined by measuring
L-DOPA accumulation after inhibition of aromatic L-amino acid decarboxylase
activity by systemic administration of NSD 1015 (Table 4).
Statistical analysis of data showed a significant effect of genotype and
area (genotype: F(1,83)=20.39, p<0.001; area: F(3,83)=64.48, p<0.001; genotype x
area: F(3,83)=2.69, p=0.051). In STOP KO mice, the accumulated L-DOPA levels
were significantly reduced in the substantia nigra plus the ventral tegmental
area (-31%, p=0.004), the striatum (-19%, p=0.009) and the nucleus accumbens (-
29%, p=0.001). Interestingly, the amplitude of the STOP KO-associated
decrease in in vivo TH activity was not significantly different in these three
areas. In contrast, L-DOPA accumulation in the frontal cortex did not differ
between STP KO and WT mice.
In order to compare the extent of decrease in DA, metabolites tissue
levels and TH activity, values in STOP KO mice were expressed as percentages
of the respective values in WT mice (Fig. 2). A significant difference was seen
between the change in DA levels and TH activity in the substantia nigra plus the
ventral tegmental area (101±17% versus 69±4%, respectively, p=0.037) and the
nucleus accumbens (37±4% versus 71±6%, respectively, p=0.012).
DA uptake in synaptosomes from the striatum and the nucleus accumbens
The kinetic parameters of [3H]-DA uptake were determined using synaptosomes





















In striatal synaptosomes, uptake of [3H]-DA, at all concentrations tested,
tended to be higher in STOP KO mice than in WT mice, with a nearly significant
increase at 100 nM [3H]-DA (+32%, (p=0.083). However, the maximal uptake
velocity Vmax and the Michaelis's constant Km were not significantly different
in the two genotypes, i.e. Vmax=19.5±2.4 and 24.5±2.1 pmol/mg prot/min,
Km=50.4±5.7 and 73.4±7.5 nM, in WT and STOP KO mice, respectively.
In contrast, uptake of [3H]-DA, at all concentrations tested in nucleus
accumbens synaptosomes, was regularly lower in STOP KO than in WT mice, with
a significant decrease at 500 nM [3H]-DA (-26%, p=0.049). The maximal uptake
velocity was significantly decreased by 24% in STOP KO mice compared to WT
mice, without any modification of DA affinity, i.e. Vmax=18.2±1.3 and 14.1±0.6
pmol/mg prot/min (p=0.024) and Km=191.3±5.2 and 185.0±2.5 nM, in WT and
STOP KO mice, respectively. Interestingly, the Km value for DA was
significantly 3-4-fold higher (p<0.001) in the nucleus accumbens than in the
striatum, in both WT and STOP KO mice.
Effects of cocaine on the locomotor activity of STOP KO versus WT mice
In order to reveal a potential functional consequence of the decreased Vmax of
[3H]-DA uptake in nucleus accumbens synaptosomes of mutant mice, we
compared the effects of acute cocaine at increasing doses on the locomotor
activity of WT versus STOP KO mice (Fig. 4).
During the 20-min habituation phase in the actimeter cages (not shown),
analysis of data showed a significant effect of genotype on the locomotor
activity (genotype: F(1,228)=4.14, p=0.045), which was increased by 29% in STOP
KO mice, as previously reported (Brun et al. 2005).
Statistical analysis of the cocaine effects on locomotor activity showed a
significant effect of genotype, dose and time (genotype: F(1,594)=15.65, p<0.001;
dose: F(4,594)=17.55, p<0.001; time: F(9,594)=18.93, p<0.001; genotype x dose:
F(4,594)=3.49, p=0.012; genotype x time: F(9,594)=4.66, p<0.001; dose x time:
F(36,594)=4.71, p<0.001; genotype x dose x time: F(36,594)=3.31, p<0.001). STOP KO
mice displayed a marked hypersensitivity to the stimulant effect of cocaine.
Whereas cocaine at 10 mg/kg had no effect on the activity of WT mice, it
increased by 842% (p<0.001) the locomotor activity of mutant mice. Moreover,
the increase induced by cocaine at 25 mg/kg was significantly higher in STOP
KO mice than WT mice (p=0.002, Fig. 4B).
Cocaine inhibition of [3H]-DA uptake in synaptosomes from the striatum and
the nucleus accumbens
The differences in the locomotor effects of cocaine in mutant versus WT





















exhibited peculiarities in STOP KO mice (Fig. 5). In fact, the concentration of
cocaine which inhibited the [3H]-DA uptake by 50% (IC50) was similar in mice of
both genotypes, i.e. IC50=99±27 and 102±33 nM in striatal and 193±24 and
205±23 nM in accumbic synaptosomes of WT and STOP KO mice, respectively.
Corresponding Ki values were 83±22 and 90±29 nM for the striatum and 183±22
and 195±22 nM for the nucleus accumbens of WT and STOP KO mice,
respectively. Finally, the Ki value of cocaine was 2.2-fold higher in the nucleus
accumbens than in the striatum in both WT and mutant mice (p=0.037).
Behavioral sensitization to cocaine in STOP KO versus WT mice
To assess the sensitivity of STOP KO mice towards sub-chronic cocaine
treatment, we measured the effects of repeated administration of cocaine in a
paradigm of behavioral sensitization (Fig. 6). We chose the lowest active dose of
cocaine in STOP KO mice (10 mg/kg, see Fig. 4). Statistical analyses of data
during the initiation phase (days 1-5) and at the expression phase (day 26)
showed a significant effect of genotype, treatment and time (genotype:
F(1,205)=6.25, p=0.017; treatment: F(1,205)=18.40, p<0.001; time: F(5,205)=19.26,
p<0.001; genotype x treatment: F(1,205)=4.78, p=0.035; genotype x time:
F(5,205)=2.19, p=0.056; treatment x time: F(5,205)=2.98, p=0.013).
In WT mice, during the initiation phase, cocaine 10 mg/kg had no effect
at day 1 (Figs. 4 and 6), but significantly increased the locomotor activity at day
5 (230% versus saline, p=0.010; 140% versus cocaine at day 1, p=0.034). After a
21-day withdrawal, during the expression phase, the effect of cocaine was
similar in saline- and cocaine-pretreated mice, suggesting an environmental
sensitization. Finally, the effect of cocaine on cocaine-treated WT mice was
significantly higher at day 26 than at day 1 (230%, p=0.001).
In STOP KO mice, during the initiation phase, 10 mg/kg cocaine
significantly enhanced the locomotor activity by 350% at day 1 (p=0.015; Figs. 4
and 6) and by 600% at day 5 (p<0.001) versus saline, indicating a 70% increase
(p=0.037) in the response from day 1 to day 5. After a 21-day withdrawal, the
effect of cocaine at day 26 in cocaine-treated mice was significantly higher























Altogether, our data show that the suppression of the relatively ubiquitous
microtubule-associated STOP protein (Andrieux et al. 2002) elicited discrete
changes in DAergic neurotransmission systems, affecting mainly the meso-limbic
pathway. Indeed, STOP KOP mice exhibited DAergic hyper-reactivity as
decreased DAergic D2 receptor level, decreased DA uptake by accumbic
synaptosomes and hypersensitivity to cocaine.
Whereas the densities of the DA transporter and the vesicular
monoamine transporter 2 were not altered in any brain area examined in STOP
KO compared to WT mice, the density of DAergic D2 receptors was decreased in
DAergic terminal areas, but not in DAergic cell bodies regions in mutant mice. In
contrast, the density of D3 receptors was decreased in both DAergic cell bodies
and terminal areas, particularly in the meso-accumbic pathway. Evidence for
higher DAergic neurotransmission in STOP KO mice has been clearly
demonstrated in previous studies (Brun et al., 2005). The decreased density of
D2 receptors, restricted to DAergic terminal areas, might well correspond to a
compensatory mechanism to elevated extracellular DA concentrations in STOP
KO mice, as previously reported in the constitutively hyperDAergic DAT KO
mice (Giros et al. 1996; Jones et al. 1998; Weiss et al. 2007), which are also
considered a pertinent model for some symptoms of schizophrenia (Gainetdinov
et al. 2001). In contrast, these changes in D3 receptor density could not be
related to some decrease in extracellular DA levels, as expected from the
paradoxical adaptive downregulation of D3 receptors in rats with decreased
DAergic tone (Levesque et al. 1995). Finally, in contrast with data in DAT KO
mice (Giros et al. 1996; Jones et al. 1998; Weiss et al. 2007), the density of D1
receptors was not modified in any area examined in STOP KO mice. This could
mean that alterations of D2 receptor density in STOP KO mice not only depend
on the DAergic area, but also on the nature of the neurons expressing D2 versus
D1 receptors.
Interestingly, our data showing the absence of alteration of D2
autoreceptor density in DA cell bodies areas did not match the previous finding
of Brun et al. (2005). Using an amperometric method, the authors reported an
enhanced autoinhibition of evoked DA release in the nucleus accumbens in STOP
KO mice. Determination of the ratio of D2 and D3 autoreceptors over
postsynaptic receptors in the nucleus accumbens of mutant mice and of their
respective coupling efficiency and functional characteristics should help to
elucidate these apparent discrepancies.
The occurrence of STOP KO-associated changes restricted to some





















metabolite levels. Whereas DA, DOPAC and HVA levels were not modified in the
substantia nigra and the ventral tegmental area containing DAergic cell bodies
of STOP KO mice, they were significantly decreased in DAergic terminal areas,
i.e. striatum and nucleus accumbens. Interestingly, the amplitude of the drop in
endogenous DA and metabolite levels was twice as high in the nucleus accumbens
as in the striatum. The decreased DA levels in STOP KO mice are reminiscent of
that reported in the striatum of DAT KO mice (Jones et al. 1998) and might be
due to an impaired transport of tyrosine hydroxylase protein from DAergic cell
bodies to terminals. However, measurement of L-DOPA accumulation after
aromatic L-amino acid decarboxylase inhibition showed that the rate of DA
synthesis was decreased to the same extent in both DAergic cell bodies and
terminals in mutant mice. This reduction might reflect alterations in the
expression and/or catalytic activity of tyrosine hydroxylase. The similar
decrease in DA synthesis in both DAergic cell bodies and terminals areas in
STOP KO mice does not explain why the decrease of endogenous DA levels was
restricted to DAergic terminals areas and the reason why the latter decrease
was twice as large in the nucleus accumbens as in the striatum. Relevant
investigations have to be performed to elucidate the actual underlying
mechanisms.
Furthermore, in the three DAergic areas examined, the decrease of
endogenous DA levels did not always parallel that of in vivo TH activity. The
difference is particularly striking in the substantia nigra plus the ventral
tegmental area where endogenous DA levels were not modified, despite a 31%
decrease of in vivo TH activity. This could be due to a diminished DA catabolism,
as indicated by the tendency of DOPAC and HVA levels to be less (-20%, ns) in
mutant mice. In the striatum, the parallel decrease of DA and metabolites levels
and of TH activity suggests that DA turn-over was not altered beyond TH step
in STOP KO mice. In the nucleus accumbens, the 69% decrease of DA levels
could not be explained by the 29% decrease of TH activity. However, the
difference could not be due to enhanced DA catabolism, because DOPAC and
HVA levels decreased to the same extent as DA levels in mutant mice.
Interestingly, previous analysis of the striatal DA turn-over in DAT KO mice
provided evidence that the reserve pools of DA are more dependent on recycled
extracellular DA than on the newly synthetized amine (Jones et al. 1998). Thus,
an increased DA release (Brun et al. 2005) associated with decreased DA
reuptake (present study) could partly explain the large drop of endogenous DA
levels in the nucleus accumbens of STOP KO mice. Another non exclusive
hypothesis which remains to be tested could be a deficit of vesicular storage of





















Finally, it is difficult to reconcile a decreased in vivo DA synthesis with
the hypothesis that the reduced density of postsynaptic D2 receptors
represents a homeostatic adaptation to higher extracellular DA level. This
discrepancy probably means that, in spite of decreased synthesis, the DA
releasable pool could be larger and/or exocytotic processus could be more
efficient in STOP KO mice. Although this hypothesis is compatible with the
hypersensitivity of mutant mice to amphetamine (Brun et al. 2005), further
experiments aimed at assessing VMAT2 functional status have to be performed
in STOP KO compared to WT mice.
Whereas DAT density was not modified in any DAergic area, DAT activity
in synaptosomes was increased in the striatum (by 30%, ns) and decreased in the
nucleus accumbens (by 25%, p<0.05) in STOP KO compared with WT mice. Such
opposite changes in DA uptake in the striatum versus the nucleus accumbens, not
observed at low DA concentrations,  paralleled previous data reported by Brun
et al. (2005) on extracellular DA levels. These authors found that electrically-
evoked DA release is decreased in the striatum, although not significantly, and,
in contrast, significantly increased in the nucleus accumbens of mutant
compared to WT mice. Further investigations are necessary to explain how
STOP protein deficiency can affect DAT activity differently in the two regions.
Another interesting feature of this study lays in the lower affinity
(higher Km value) of DAT for DA in the nucleus accumbens compared with the
striatum, in mice of both genotypes. To our knowledge, the kinetic parameters
of DA uptake by synaptosomes from the mouse nucleus accumbens have never
been reported. Such regional difference in DA affinity may be underlain by the
association of DAT with chaperone proteins which may vary in an area-
dependent manner, in agreement with previous studies showing a 10-fold lower
affinity of DA for DAT in cultured cells than in striatal synaptosomes (Giros et
al. 1992; Giros and Caron, 1993).
To assess potential functional consequences of altered DA reuptake in
STOP KO mice, we tested the response of mutant mice to the acute locomotor
effect of the DAT inhibitor cocaine. STOP KO mice displayed a clear-cut
hypersensitive response to the stimulatory effect of cocaine on locomotion, as
previously reported for amphetamine (Brun et al. 2005). Indeed, the cocaine
dose-response curve showed a 10-fold leftward shift in mutant compared with
WT mice. In addition, we showed that cocaine-induced behavioral sensitization
persisted much longer in STOP KO mutants (up to at least 21 days) than in WT
mice. The hypersensitivity of mutant mice was not related to some alterations in
DA uptake inhibition by cocaine, because the latter drug was equally potent in
mice of both genotypes. Hypersensitivity of STOP KO mice might rather be due





















coupling and/or downstream signaling pathways. Another non exclusive
explanation could be that cocaine partly mediates its effects via another
monoamine transporter, such as the serotonin transporter for which it displays a
high affinity (Giros et al. 1992). Indeed, serotonin neurotransmission is probably
altered in STOP KO mice, in line with previous data demonstrating marked
anxiety-like behavior in these mice (Andrieux et al. 2002). In addition, the
implication of the NA transporter cannot be ruled out because cocaine also
displays some affinity for this transporter (Giros et al. 1992) and because its
affinity for DAT was two-fold lower in accumbic than in striatal synaptosomes
from mice of both genotypes.
Altogether our study shows that genetic deletion of the microtubule-
regulating STOP protein can induce significant adaptations of dopaminergic
neurotransmission, further supporting the idea that STOP KO mice are a
relevant model for the study of some symptoms of schizophrenia. In agreement
with previous results (Brun et al. 2005), we showed that mutant mice displayed
DAergic hyper-reactivity preferentially in the meso-limbic pathway. This
suggests a probable hyperDAergia as in schizophrenia, even if no alterations of
D2 and D3 receptor density, endogenous DA level and in vivo DA synthesis have
been reported in schizophrenic brain (Gurevich et al. 1997, Seeman and Kapur
2000). Interestingly, STOP KO mice were also hyper-responsive to
psychostimulants, in agreement with co-morbidity of schizophrenia and drug
abuse (Batel 2000; Winklbaur et al. 2006). To conclude, our study and previous
works clearly indicate that the deletion of a relatively ubiquitous structural
protein (Couegnas et al. 2007) can translate into specific and restricted
alterations of glutamatergic (Andrieux et al. 2002; Brenner et al. 2007),
dopaminergic (Brun et al. 2005 and this study) and nicotinic neurotransmission
(Bouvrais-Veret et al. 2007). This is what happens in humans, where
deletion/mutation of single genes broadly distributed can actually be responsible
for specific symptoms (Jamain et al. 2003; Ishizuka et al. 2006).
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Table 1: Density of DA transporters in various brain areas of STOP KO
versus WT mice
Transporter Area WT KO KO/WT
DAT SNc (6) 353 ± 11 (5) 370 ± 19 +5% ns
VTA (5) 355 ± 13 (5) 387 ± 21 +9% ns
Striatum (6) 359 ± 8 (6) 360 ± 12  0%
N Acc (5) 314 ± 7 (5) 326 ± 13 +4% ns
Core (5) 350 ± 11 (6) 362 ± 13 +3% ns
Shell (5) 279 ± 9 (6) 291 ± 19 +4% ns
VMAT2 SN (5) 571 ± 16 (4) 581 ± 28 +2% ns
VTA (4) 265 ± 27 (4) 241 ± 27 -9% ns
Striatum (5) 436± 25 (5) 482 ± 44 +11% ns
N Acc (5) 494 ± 30 (5) 519 ± 24 +5% ns
Core (5) 454 ± 42 (5) 499 ± 37 +10% ns
Shell (5) 533 ± 32 (5) 538 ± 25 +1% ns
Densities are the means ± SEM of specific autoradiographic labellings in
arbitrary mean grey values. The number of mice is indicated in parentheses.
Core: nucleus accumbens, core part; N Acc, nucleus accumbens; Shell: nucleus
accumbens, shell part; SN, substantia nigra; SNc, substantia nigra, pars





















Table 2: Density of DA receptors in various brain areas of STOP KO versus
WT mice
Receptor Area WT KO KO/WT
D1 SNr (6) 131 ± 4 (6) 132 ± 7  0%
Striatum (5) 494 ± 10 (5) 486 ± 21 -2% ns
N Acc (5) 338 ± 8 (5) 340 ± 16 +1% ns
Core (5) 356 ± 7 (5) 332 ± 16 -7% ns
Shell (5) 324 ± 12 (5) 358 ± 14 +11% ns
D2 SNc (5) 264 ± 33 (5) 231 ± 11 -12% ns
VTA (5) 237 ± 18 (4) 211 ± 11 -11% ns
Striatum (6) 774 ± 70 (6) 596 ± 50 -23% *
N Acc (5) 280 ± 28 (5) 202 ± 11 -28% *
Core (5) 257 ± 23 (5) 185 ± 14 -28% *
Shell (5) 240 ± 22 (5) 175 ± 15 -27% *
D3 SN (6) 21.3 ± 1.1 (5)  18.8± 2.2 -12% ns
SNmc (6) 46.9 ± 2.0 (5) 35.7 ±4.0 -24% *
SNr (6) 14.8 ±0.7 (5) 13.9 ± 1.0 -6% ns
VTA (6) 14.3 ± 0.8 (4) 8.9 ± 1.9 -37% *#
Striatum (6) 16.7 ±1.1 (6) 18.0 ±1.6 +8% ns
N Acc (6) 68.9 ±2.3 (6) 56.7 ± 3.9 -18% *##
Core (6) 70.3 ± 4.8 (6) 53.3 ± 4.8 -24% *
Shell (6) 103.2 ± 4.6 (6) 81.6 ± 5.3 -21% *
Densities are the means ± SEM of specific autoradiographic labellings in
arbitrary mean grey values. The number of mice is indicated in parentheses.
Core: nucleus accumbens, core part; N Acc, nucleus accumbens; Shell: nucleus
accumbens, shell part; SN, substantia nigra; SNc, substantia nigra, pars
compacta; SNmc, substantia nigra, median pars compacta; SNr, substantia
nigra, pars reticulata; VTA, ventral tegmental area. Post hoc Fisher's test:
*p<0.05, comparison between genotypes; #p<0.05, comparison with SN in STOP





















Table 3: DA, DOPAC and HVA levels in various brain areas of WT and STOP KO
mice
 Area Genotype DA DOPAC HVA




























Levels (µg/g tissue) of DA and its metabolites HVA and DOPAC are expressed as
means ± SEM. The number of mice is indicated in parentheses. Fr Cx, frontal
cortex; N Acc, nucleus accumbens; SN+VTA, substantia nigra + ventral
tegmental area.
Post hoc Fisher's test: *p<0.05; **p<0.01; ***p<0.001, comparison between






















Table 4: In vivo activity of tyrosine hydroxylase in various brain areas of WT
and STOP KO mice
L-DOPA (ng/g)Area
WT KO KO/WT
SN+VTA (12) 861±55 (12) 590±38 -31% ***
Striatum (10) 1405±83 (12) 1145±63 -19% **
N Acc (11) 1188±108 (11) 846±76 -29% ***
Fr Cx (11) 382±32 (12) 395±58 +3% ns
Mice received 100 mg/kg NSD 1015 30 minutes before sacrifice. Respective basal
endogenous L-DOPA levels were subtracted from L-DOPA accumulated after NSD
1015 administration. L-DOPA levels (ng/g tissue) are expressed as means ± SEM.
The number of mice is indicated in parentheses. Fr Cx, frontal cortex; N Acc,
nucleus accumbens; SN+VTA, substantia nigra + ventral tegmental area.






















Fig. 1 Representative autoradiographic labelling of plasmic DA (DAT) and
vesicular monoamine (VMAT2) transporters and of D1, D2 and D3 DAergic
receptors in brain areas of WT and STOP KO mice. N Acc, nucleus accumbens,
SNc, substantia nigra, pars compacta; SNr, substantia nigra, pars reticulata;
VTA, ventral tegmental area.
Fig. 2 Comparison of the variations of tissue DA and metabolite levels with
tyrosine hydroxylase activity in DAergic areas of STOP KO mice.
Values of endogenous DA and metabolite (MET) levels and of TH activity are
expressed as means ± SEM of percentages of respective values in WT mice. Fr
Cx, frontal cortex; N Acc, nucleus accumbens; SN+VTA, substantia nigra +
ventral tegmental area; Str, striatum.
Post hoc Fisher’s test: ∗ p < 0.05, ∗∗ p < 0.01, comparison between DA and TH;
# p < 0.05, comparison with WT (100%).
Fig. 3 DA uptake in synaptosomes from the striatum and the nucleus accumbens
of STOP KO versus WT mice.
Values represent means ± SEM in pmol [3H]DA taken up /min /mg prot from 3
(striatum) and 6 (nucleus accumbens) independent experiments, each on pooled
areas from two WT or KO mice.
Fig. 4 Effect of acute administration of cocaine on the locomotor activity of
STOP KO versus WT mice.
A: Time course of the locomotor activity of WT and STOP KO mice after
administration of cocaine at increasing doses. Means ± SEM of photocell counts
per 5 min period. B: Dose-response effects of cocaine administration on the
locomotor activity of WT and STOP KO mice. Data represent means ± SEM of
photocell counts over a 50 min period for 9 WT and 10 KO at cocaine 0, 8 WT
and 9 KO at cocaine 5, 8 WT and 7 KO at cocaine 10 and 7 WT and 7 KO at
cocaine 25 and 40 mg/kg.
Post hoc Fisher’s test: ∗ p<0.05,  ∗∗∗ p<0.001, comparison with the saline group of
the same genotype; ## p<0.01, ### p<0.001, comparison between genotypes.
Fig. 5 Inhibition of [3H]DA uptake by cocaine in synaptosomes from the
striatum and the nucleus accumbens of STOP KO versus WT mice.
Uptake of 10 nM [3H]DA in the presence of cocaine at increasing concentrations.





















Means ± SEM of 3 independent experiments, each on pooled areas from two WT
or KO mice.
Fig. 6 Behavioral sensitization to cocaine of WT and STOP KO mice.
Top: Horizontal locomotor activity of WT and STOP KO mice after
administration of saline (Sal) or cocaine 10 mg/kg (Coc), once daily for 5 days.
After a treatment-free period of 20 days, all mice received saline at day 25 (25
Sal) and cocaine 10 mg/kg at day 26 (26 Coc). Means ± SEM of counts over 60
min from 12 WT Sal, 11 WT Coc, 12 KO Sal and 10 KO Coc. Bottom: Cumulated
counts over 60 min period, after cocaine administration, at day 1 (acute
administration), day 5 (end of the acquisition period) and at day 26 (expression
period) for saline-pretreated or cocaine-pretreated mice.
Post hoc Fisher’s test: * p<0.05, ** p<0.01, *** p<0.01, comparison with the saline
group; # p<0.05, ### p<0.001, comparison of cocaine effect between day.
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